ArticleOncology letters2014

Low dose of interferon-α improves the clinical outcomes of docetaxel in patients with castration-resistant prostate cancer: A pilot study.

Yun-Fei Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.